DiaMedica Therapeutics says first patient dosed in relaunch of DM199 trial

The company states: “DiaMedica Therapeutics announced the first patient being dosed in DiaMedica’s relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment of acute ischemic stroke. The company continues to work closely with its contract research organization, on re-engaging with study sites for the ReMEDy2 Trial. The trial is intended to enroll approximately 350 patients at up to 100 sites globally. The majority of the U.S. sites are expected to be activated by the end of the third quarter of 2024. With the support of the Canadian Stroke Consortium, the activation of study sites in Canada is expected to begin in the third quarter of 2024. In Australia, the Company has received provisional endorsement from the Australian Stroke Trials Network and Australian site activation is expected to commence in the fourth quarter of 2024. Initial steps are also being taken to expand ReMEDy2 into the United Kingdom, Spain, and select other European countries.”